Status:
UNKNOWN
Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT
Lead Sponsor:
Shandong Provincial Hospital
Conditions:
Stem Cell Transplant Complications
Eligibility:
All Genders
Phase:
NA
Brief Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for many malignant or nonmalignant hematological diseases. Hemorrhagic cystitis (HC) is one of the comm...
Eligibility Criteria
Inclusion
- Patients undergoing allogeneic stem cell transplantation
- Patients develop late-onset hemorrhagic cystitis (HC)
- The count of neutrophilia cells over 0.5 \* 10\^9/L, hemoglobin over 60 g/L, platelet over 30 \*10\^9/L
- SGOT/SGPT no more than 2 times of UNL
- Serum creatinine no more than 1.5 times of UNL
- Signed informed consent
Exclusion
- Early-onset HC post-allo-HSCT
- Unsuitable to the study due to severe complication such as uncontrolled severe infection
- Claustrophobia
- Ear diseases such as otitis media
- Eye diseases such as glaucoma
- Epilepsy history
- Important organ dysfunction
- Coagulopathy
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04502628
Start Date
September 1 2021
End Date
December 31 2024
Last Update
September 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shandong Provincial Hospital
Jinan, Shandong, China, 250021